Diabetes in Children and Teens
Methodology & AI Transparency ⓘ
Diabetes in Children and Teens Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Until recently, the common type of diabetes in children and teens was type 1 .
- 2 Real-world patient consensus: Clinical coding for Diabetes in Children and Teens uses ICD-10 R73.5 across Diabetes & Glucose specialty care.
- 3 Typical cash cost range: Primary evaluation for Diabetes in Children and Teens incorporates fasting insulin/C-peptide quantification [Diabetes in Children and Teens R73.5] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Diabetes in Children and Teens monitoring tracks CGM Time-in-Range (70–140 in Diabetes in Children and Teens (R73.5: mg/dL)) toward > 85% (R73.5).
Ask our AI Specialists anything about Diabetes in Children and Teens
What Is Diabetes in Children and Teens?
Until recently, the common type of diabetes in children and teens was type 1 . It was called juvenile diabetes. With Type 1 diabetes, the pancreas does not make insulin. Insulin is a hormone that helps glucose,or sugar, get into your cells to give them energy. Without insulin, too much sugar stays in the blood. Now younger people are also getting type 2 diabetes . Type 2 diabetes used to be called adult-onset diabetes. But now it is becoming more common in children and teens, due to more obesity . With Type 2 diabetes, the body does not make or use insulin well.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Diabetes in Children and Teens (R73.5) center on impaired incretin GLP-1/GIP in Diabetes in Children and Teens (R73.5: signaling). Cross-referenced with NIH MeSH (Diabetes Mellitus), targeted diabetes & glucose interventions aim to normalize CGM Time-in-Range (70–140 in Diabetes in Children and Teens (R73.5: mg/dL)).
Common Symptoms & Clinical Signs
- • Have them maintain a healthy weight
- • Be sure they are physically active
- • Presentation of Diabetes in Children and Teens (R73.5): increased thirst [Diabetes in Children and Teens R73.5]
- • Secondary Diabetes in Children and Teens clinical sign: postprandial afternoon energy in Diabetes in Children and Teens (R73.5: crashes and carbohydrate)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Diabetes in Children and Teens Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R73.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Diabetes in Children and Teens (R73.5: mg/dL)) | > 85% (R73.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Diabetes in Children and Teens R73.5] | 4.8% – 5.6% (< 6.5% clinical target) (R73.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetes in Children and Teens R73.5] | 75 – 95 mg/dL (R73.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetes in Children and Teens
Treatment selection for Diabetes in Children and Teens depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetes in Children and Teens)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Diabetes in Children and Teens Patient Community & “People Like Me” Threads
Filter Diabetes in Children and Teens community threads and patient logs by age, biological sex, dosage, and treatment duration.